Author

S. de Carne Trecesson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:differential expression· 1

Frequent Co-Authors

J. Downward· 3 shared P. East· 3 shared C. Moore· 2 shared C. Swanton· 2 shared E. Mugarza· 2 shared J. Boumelha· 2 shared M. Molina-Arcas· 2 shared S. Rana· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Downward

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivApr 13, 2023

CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer

J. Boumelha, A. de Castro, N. Bah…·J. Downward

The paper identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer through CRISPR/Cas9 screening and shows targeting COX-2 enhances immune checkpoint blockade efficacy.

DOI 10.1158/0008-5472.can-23-2627

mousehuman

𝕏 PostBluesky

Cancer BiologybioRxivApr 2, 2021

Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma

P. East, G. Kelly, D. Biswas…·J. Downward

This study develops a transcriptional signature to measure RAS pathway activity in lung adenocarcinoma, showing it better predicts chemotherapy response and prognosis than KRAS mutation status.

DOI 10.1038/s41467-022-33290-0

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivDec 22, 2020

An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

J. Boumelha, S. de Carne Trecesson, E. Law…·J. Downward

This paper develops an immunogenic mouse model of KRAS-mutant lung cancer that responds to immunotherapy and reveals immune responses target endogenous retroviral antigens rather than neoantigens.

DOI 10.1158/0008-5472.can-22-0325

mouseexperimental assay

𝕏 PostBluesky